← Leaderboards
Gary E Gallick
University Of Texas Md Anderson Can Ctr
$2,839,607
Attributed
$2,839,607
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $261.3K · FY2009–19$500K$375K$250K$125K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$2,839,607 · 4
By mechanism
P50$1,811,777 · 2
R01$881,474 · 1
U19$146,356 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Texas Md Anderson Can Ctr
Same institution · by research overlap
- Christopher J. Logothetis$3,304,781
- Scott M Lippman$54,535,308
- Colin P Dinney$4,248,660
- Elizabeth A Grimm$11,275,665
- Jean-Pierre J Issa$21,637,643
Others in their field
Top investigators on “Base”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$613,567,095
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Larry Arthur$521,411,998
- Leonard Freedman · Leidos Biomedical Research, Inc.$515,995,429
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$507,042,060
Research focus
BaseResearch PersonnelMalignant Neoplasm Of ProstateLaboratoriesResponseCancer CenterClinical TrialsCellsClinical Trials DesignCase StudyAffectBiological ModelsClinical MarkersBiopsyBone RemodelingCessation Of LifeBone PreservationBone NeoplasmsCandidate MarkerBone TurnoverBasic ScienceBone CellBinding SitesBone
Grant awards (14)
Career Enhancement Program$154,857
P50 · FY2019 · CA · contact PI
Career Enhancement Program$173,555
P50 · FY2018 · CA · contact PI
Career Enhancement Program$155,727
P50 · FY2017 · CA · contact PI
Career Enhancement Program$75,200
P50 · FY2016 · CA · contact PI
Scr as a Therapeutic Target in Prostate Cancer Bone Metastases$239,159
P50 · FY2013 · CA · contact PI
Scr as a Therapeutic Target in Prostate Cancer Bone Metastases$261,283
P50 · FY2012 · CA · contact PI
Scr as a Therapeutic Target in Prostate Cancer Bone Metastases$249,662
P50 · FY2011 · CA · contact PI
Scr as a Therapeutic Target in Prostate Cancer Bone Metastases$251,203
P50 · FY2010 · CA · contact PI
Scr as a Therapeutic Target in Prostate Cancer Bone Metastases$251,131
P50 · FY2009 · CA · contact PI
SRC KINASES IN COLON TUMORIGENESIS AND METASTASIS$230,233
R01 · FY2003 · CA
SRC KINASES IN COLON TUMORIGENESIS AND METASTASIS$223,528
R01 · FY2002 · CA
SRC KINASES IN COLON TUMORIGENESIS AND METASTASIS$217,017
R01 · FY2001 · CA
SRC KINASES IN COLON TUMORIGENESIS AND METASTASIS$210,696
R01 · FY2000 · CA
CELLULAR AND ANIMAL STUDIES OF SRC INHIBITORS$146,356
U19 · FY2000 · CA